Seres files prior financials for proxy on VOWST asset sale; auditor flags going concern

Seres Therapeutics, Inc.

Furnishes 2022-2023 audited financial statements for incorporation in proxy statement related to sale of VOWST microbiome assets.
Auditor notes substantial doubt about ability to continue as going concern due to recurring losses and negative cash flows.
Financial statements consistent with prior Form 10-K filed March 5, 2024; no updates for subsequent events.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.